Magnolol
| Names | |
|---|---|
| IUPAC name
3,3′-Neoligna-8,8′-diene-4,4′-diol | |
| Systematic IUPAC name
5,5′-Di(prop-2-en-1-yl)[1,1′-biphenyl]-2,2′-diol | |
| Other names
Dehydrodichavicol 5,5'-Diallyl-2,2'-dihydroxybiphenyl 5,5'-Diallyl-2,2'-biphenyldiol | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.127.908 |
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C18H18O2 | |
| Molar mass | 266.340 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Magnolol is an organic compound that is classified as lignan. It is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis) and in M. grandiflora.
Magnolol is a compound that acts on GABA_A receptors and functions as an allosteric modulator. It has antifungal properties and demonstrates anti-periodontal disease effects in animal models. In cell cultures, magnolol stimulates osteoblasts and inhibits osteoclasts, indicating potential for anti-osteoporosis treatment. It also binds in a dimeric form to PPARγ, acting as an agonist of this nuclear receptor. Additionally, magnolol may interact with cannabinoid receptors, acting as a partial agonist of CB2 receptors with lower affinity for CB1 receptors.